Modeling Oncogenic Signaling in Colon Tumors by Multidirectional Analyses of Microarray Data Directed for Maximization of Analytical Reliability
Overview
Authors
Affiliations
Background: Clinical progression of colorectal cancers (CRC) may occur in parallel with distinctive signaling alterations. We designed multidirectional analyses integrating microarray-based data with biostatistics and bioinformatics to elucidate the signaling and metabolic alterations underlying CRC development in the adenoma-carcinoma sequence.
Methodology/principal Findings: Studies were performed on normal mucosa, adenoma, and carcinoma samples obtained during surgery or colonoscopy. Collections of cryostat sections prepared from the tissue samples were evaluated by a pathologist to control the relative cell type content. The measurements were done using Affymetrix GeneChip HG-U133plus2, and probe set data was generated using two normalization algorithms: MAS5.0 and GCRMA with least-variant set (LVS). The data was evaluated using pair-wise comparisons and data decomposition into singular value decomposition (SVD) modes. The method selected for the functional analysis used the Kolmogorov-Smirnov test. Expressional profiles obtained in 105 samples of whole tissue sections were used to establish oncogenic signaling alterations in progression of CRC, while those representing 40 microdissected specimens were used to select differences in KEGG pathways between epithelium and mucosa. Based on a consensus of the results obtained by two normalization algorithms, and two probe set sorting criteria, we identified 14 and 17 KEGG signaling and metabolic pathways that are significantly altered between normal and tumor samples and between benign and malignant tumors, respectively. Several of them were also selected from the raw microarray data of 2 recently published studies (GSE4183 and GSE8671).
Conclusion/significance: Although the proposed strategy is computationally complex and labor-intensive, it may reduce the number of false results.
Downregulation of solute carrier family 4 members 4 as a biomarker for colorectal cancer.
Pawar K, Gupta P, Solanki P, Niraj R, Kothari S Discov Oncol. 2025; 16(1):229.
PMID: 39988623 PMC: 11847767. DOI: 10.1007/s12672-025-01948-y.
Pang L, Sun Q, Wang W, Song M, Wu Y, Shi X Heliyon. 2025; 11(3):e42237.
PMID: 39944338 PMC: 11815678. DOI: 10.1016/j.heliyon.2025.e42237.
Liu M, Wang T, Li M Int J Mol Sci. 2025; 26(2).
PMID: 39859340 PMC: 11765793. DOI: 10.3390/ijms26020625.
Targeting KAT7 inhibits the progression of colorectal cancer.
Wang H, Guan T, Hu R, Huang Z, Liang Z, Lin X Theranostics. 2025; 15(4):1478-1495.
PMID: 39816686 PMC: 11729548. DOI: 10.7150/thno.106085.
CPT1A mediates radiation sensitivity in colorectal cancer.
Chen Z, Yu L, Zheng Z, Wang X, Guo Q, Chen Y Elife. 2024; 13.
PMID: 39607749 PMC: 11604221. DOI: 10.7554/eLife.97827.